Department of Critical Care Medicine, Seoul National University Hospital, Seoul, Korea.
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Korean J Intern Med. 2024 May;39(3):477-487. doi: 10.3904/kjim.2023.347. Epub 2024 Apr 18.
BACKGROUND/AIMS: Risk factors for progression to critical illness in hospital-acquired coronavirus disease 2019 (COVID-19) remain unknown. Here, we assessed the incidence and risk factors for progression to critical illness and determined their effects on clinical outcomes in patients with hospital-acquired COVID-19.
This retrospective cohort study analyzed patients admitted to the tertiary hospital between January 2020 and June 2022 with confirmed hospital-acquired COVID-19. The primary outcome was the progression to critical illness of hospital- acquired COVID-19. Patients were stratified into high-, intermediate-, or low-risk groups by the number of risk factors for progression to critical illness.
In total, 204 patients were included and 37 (18.1%) progressed to critical illness. In the multivariable logistic analysis, patients with preexisting respiratory disease (OR, 3.90; 95% CI, 1.04-15.18), preexisting cardiovascular disease (OR, 3.49; 95% CI, 1.11-11.27), immunocompromised status (OR, 3.18; 95% CI, 1.11-9.16), higher sequential organ failure assessment (SOFA) score (OR, 1.56; 95% CI, 1.28-1.96), and higher clinical frailty scale (OR, 2.49; 95% CI, 1.62-4.13) showed significantly increased risk of progression to critical illness. As the risk of the groups increased, patients were significantly more likely to progress to critical illness and had higher 28-day mortality.
Among patients with hospital-acquired COVID-19, preexisting respiratory disease, preexisting cardiovascular disease, immunocompromised status, and higher clinical frailty scale and SOFA scores at baseline were risk factors for progression to critical illness. Patients with these risk factors must be prioritized and appropriately isolated or treated in a timely manner, especially in pandemic settings.
背景/目的:导致医院获得性 2019 冠状病毒病(COVID-19)进展为危重症的危险因素仍不清楚。在这里,我们评估了医院获得性 COVID-19 患者进展为危重症的发生率和危险因素,并确定了它们对患者临床结局的影响。
这项回顾性队列研究分析了 2020 年 1 月至 2022 年 6 月期间在三级医院住院并确诊为医院获得性 COVID-19 的患者。主要结局是医院获得性 COVID-19 进展为危重症。根据进展为危重症的危险因素数量,患者被分为高危、中危或低危组。
共纳入 204 例患者,其中 37 例(18.1%)进展为危重症。多变量逻辑分析显示,患有既往呼吸系统疾病(比值比,3.90;95%置信区间,1.04-15.18)、既往心血管疾病(比值比,3.49;95%置信区间,1.11-11.27)、免疫功能低下状态(比值比,3.18;95%置信区间,1.11-9.16)、较高的序贯器官衰竭评估(SOFA)评分(比值比,1.56;95%置信区间,1.28-1.96)和较高的临床虚弱评分(比值比,2.49;95%置信区间,1.62-4.13)的患者进展为危重症的风险显著增加。随着风险组的增加,患者进展为危重症的可能性显著增加,28 天死亡率也更高。
在医院获得性 COVID-19 患者中,既往呼吸系统疾病、既往心血管疾病、免疫功能低下状态以及基线时较高的临床虚弱评分和 SOFA 评分是进展为危重症的危险因素。这些有风险的患者必须被优先考虑,并及时进行适当的隔离或治疗,尤其是在大流行期间。